Michael Dolker

571 total citations
9 papers, 470 citations indexed

About

Michael Dolker is a scholar working on Pulmonary and Respiratory Medicine, Cardiology and Cardiovascular Medicine and Physiology. According to data from OpenAlex, Michael Dolker has authored 9 papers receiving a total of 470 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 3 papers in Cardiology and Cardiovascular Medicine and 3 papers in Physiology. Recurrent topics in Michael Dolker's work include Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers), Asthma and respiratory diseases (2 papers) and Respiratory Support and Mechanisms (2 papers). Michael Dolker is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (4 papers), Asthma and respiratory diseases (2 papers) and Respiratory Support and Mechanisms (2 papers). Michael Dolker collaborates with scholars based in United States, United Kingdom and Japan. Michael Dolker's co-authors include Tim Overend, J. Marcus Wharton, William Smith, Anthony Tang, Raymond E. Ideker, Seitaro Yabe, George L. Bakris, Iris Kingma, Brent M. Egan and David A. Calhoun and has published in prestigious journals such as Journal of the American College of Cardiology, Thorax and Obstetrics and Gynecology.

In The Last Decade

Michael Dolker

9 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Dolker United States	7	202	194	156	76	62	9	470
Justina Motiejūnaitė France	7	44 0.2×	61 0.3×	128 0.8×	14 0.2×	35 0.6×	16	352
Brian H. Negus United States	10	40 0.2×	42 0.2×	258 1.7×	44 0.6×	56 0.9×	12	529
Mary Barrowcliffe United Kingdom	11	30 0.1×	130 0.7×	42 0.3×	23 0.3×	28 0.5×	16	377
Antonio C. Quiroz United States	13	50 0.2×	71 0.4×	252 1.6×	20 0.3×	21 0.3×	35	434
Ikuko Miyawaki Japan	11	144 0.7×	28 0.1×	90 0.6×	16 0.2×	12 0.2×	45	351
Matthias Paul Germany	14	51 0.3×	115 0.6×	138 0.9×	39 0.5×	19 0.3×	20	629
Steve Fisher New Zealand	8	132 0.7×	78 0.4×	254 1.6×	20 0.3×	6 0.1×	10	521
H. Selldén Sweden	11	82 0.4×	180 0.9×	56 0.4×	15 0.2×	27 0.4×	23	349
David Vega United States	10	30 0.1×	121 0.6×	230 1.5×	170 2.2×	15 0.2×	16	590
Tetsufumi Sato Japan	12	60 0.3×	43 0.2×	113 0.7×	12 0.2×	60 1.0×	39	449

Countries citing papers authored by Michael Dolker

Since Specialization

Citations

This map shows the geographic impact of Michael Dolker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Dolker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Dolker more than expected).

Fields of papers citing papers by Michael Dolker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Dolker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Dolker. The network helps show where Michael Dolker may publish in the future.

Co-authorship network of co-authors of Michael Dolker

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Dolker. A scholar is included among the top collaborators of Michael Dolker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Dolker. Michael Dolker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Verkindre, C., et al.. (2010). Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respiratory Medicine. 104(10). 1482–1489. 59 indexed citations

Noord, J.A. van, Roland Buhl, Craig LaForce, et al.. (2010). QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 65(12). 1086–1091. 90 indexed citations

Fabbri, Leonardo M., et al.. (2010). Cardiovascular Safety of QVA149, a Combination of Indacaterol and NVA237, in COPD Patients. COPD Journal of Chronic Obstructive Pulmonary Disease. 7(6). 418–427. 51 indexed citations

Overend, Tim, Yimeng Lu, Michael Dolker, & Donald Banerji. (2010). Dose Response Of NVA237, A Long-acting Muscarinic Antagonist For The Treatment Of COPD. A4422–A4422. 2 indexed citations

Bakris, George L., et al.. (2002). Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. Journal of Hypertension. 20(11). 2257–2267. 81 indexed citations

Boerrigter, Peter J., Herman Ellman, & Michael Dolker. (1999). International clinical experience with a new low-dose, Monophasic oral contraceptive containing levonorgestrel 100 μg and ethinyl estradiol 20 μg. Clinical Therapeutics. 21(1). 118–127. 17 indexed citations

Ellman, Herman, et al.. (1999). A Randomized Controlled Trial of Four Doses of Transdermal Estradiol for Preventing Postmenopausal Bone Loss. Obstetrics and Gynecology. 94(3). 330–336. 4 indexed citations

Kashanian, Franciska K., et al.. (1990). Rapid bolus injection of gadopentetate dimeglumine: absence of side effects in normal volunteers.. American Journal of Neuroradiology. 11(5). 853–856. 22 indexed citations

Tang, Anthony, Seitaro Yabe, J. Marcus Wharton, et al.. (1989). Ventricular defibrillation using biphasic waveforms: The importance of phasic duration. Journal of the American College of Cardiology. 13(1). 207–214. 144 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact